Cell therapy for hard-to-treat scleroderma
Treatments studied
Part of Skin clinical trials.
This study tests an experimental cell therapy (UTAA91) for people with hard-to-treat scleroderma. The goal is to see if this treatment can help when other options haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have moderate to severe scleroderma that hasn't improved with standard treatments.
- Your doctor expects you to live at least 3 more months.
- Your liver, kidneys, and heart/lungs are working well enough for this treatment.
- You have not had CAR-T therapy or other gene-modified cell treatments before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment, UTAA91 injection, for people with moderate-to-severe systemic sclerosis that hasn't improved with standard therapies. It may offer an option when other treatments have failed or aren't available.
This trial tests whether stem cells from umbilical cord blood can help treat systemic sclerosis (scleroderma). The goal is to see if this treatment can improve skin thickening and overall symptoms for people who haven't had success with standard therapies.
This trial tests a new cell therapy (CT1190B) for people with moderate to severe lupus or systemic sclerosis that has not responded to standard treatments. The therapy aims to calm the overactive immune system causing these autoimmune diseases.
This trial tests a new treatment using your own immune cells, modified to attack faulty cells that drive systemic sclerosis. It's for people with active disease who haven't improved with standard therapies.
This trial is testing a new type of cell therapy called universal CAR-T cells combined with immunosuppressant drugs for people with hard-to-treat autoimmune diseases. The goal is to see if this approach is safe and can help reduce disease activity.
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.